Genitourinary Cancers Symposium (ASCO GU) | Conference

Men with Testicular Cancer More Likely to Develop Prostate Cancer

February 23rd 2015

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

AR-V7 Not Predictive of Chemo Outcomes in mCRPC, But May Still Have Prognostic Value

February 23rd 2015

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

February 28th 2014

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Dr. Beer on the Implications of the PREVAIL Study

February 3rd 2014

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Dr. Fosså on Radiotherapy/ Antiandrogen Therapy

February 3rd 2014

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

PD-L1 Expression Independent Prognostic Indicator in mRCC

February 3rd 2014

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

New Combinations Show Activity in Advanced Urothelial Cancer

February 1st 2014

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

Dr. Figlin Describes the Efficacy of AGS-003 in mRCC

February 1st 2014

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Survival Remains Unchanged in Metastatic Urothelial Cancer Despite Increasing Use of Second-Line Therapies

February 1st 2014

Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.

Dr. Oh on Validating Gene Signatures in mCRPC

February 1st 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

Role of Corticosteroids Unclear for Men With mCRPC

January 31st 2014

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

Three Studies Provide Insights About Combining/Sequencing Abiraterone

January 31st 2014

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

Dr. Pal on RCS in Metastatic Urothelial Carcinoma

January 31st 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

Follow-up Confirms Safety of Radium-223 in mCRPC

January 31st 2014

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

Dr. Gomella Discusses New Data on Sipuleucel-T

January 31st 2014

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

Dr. Neal Shore Discusses ODM-201 in CRPC

January 30th 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC

January 30th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

Long-Term Data Show Continued Improved Outcomes for Radiotherapy/Antiandrogen Combination in Locally Advanced Prostate Cancer

January 29th 2014

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%

January 28th 2014

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies

January 28th 2014

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

NEXT PAGE
PREVIOUS PAGE